Inconclusive HIV-1/2 results: how far should blood centers go?
| Autor: | Maria Virgínia C. Lima-Martins, Ester Barezani, Alcione M. de Pinho, Eric Bassetti-Soares, Cristiane Amorim Andrade, Anna Bárbara F. Carneiro-Proietti |
|---|---|
| Jazyk: | angličtina |
| Předmět: |
Microbiology (medical)
Adult Male HBsAg medicine.medical_specialty Lymphoid Tissue Human immunodeficiency virus (HIV) lcsh:QR1-502 Blood Donors medicine.disease_cause Hepatitis b surface antigen lcsh:Microbiology lcsh:Infectious and parasitic diseases Immunoenzyme Techniques Health services HIV Seroprevalence Internal medicine medicine Humans lcsh:RC109-216 medicine.diagnostic_test business.industry Blood collection Middle Aged Predictive value Infectious Diseases Blood Immunoassay Immunology HIV-2 HIV-1 Blood Banks Blood supply Female business Brazil |
| Zdroj: | Brazilian Journal of Infectious Diseases, Vol 5, Iss 3, Pp 161-162 Brazilian Journal of Infectious Diseases, Vol 5, Iss 3, Pp 161-162 (2001) Brazilian Journal of Infectious Diseases, Volume: 5, Issue: 3, Pages: 161-162, Published: JUN 2001 |
| ISSN: | 1678-4391 |
| Popis: | Testing of donated blood for blood transmittable diseases started in 1971 with hepatitis B surface antigen (HBsAg). The first blood-screening test to detect HIV was licensed in 1985 and was quickly implemented by blood banks to ensure safety of the blood supply and protect transfusion recipients. Testing for transfusion transmittable infections in low prevalence populations tends to produce low positive predictive values. The choice of a high or a low cut-off level for screening depends therefore on the relative importance we attach to false positive and false negative results. Blood donors who test reactive (repeatedly or not) on enzyme immunoassay (EIA) and are not confirmed as positive are an ongoing problem for blood collection centers. Reactive units are discarded although donors may be uncontaminated with the infectious agents. (excerpt) |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|